Mounjaro becomes the first GIP/GLP-1 receptor agonist cleared to lower MACE risk, based on the SURPASS-CVOT head-to-head trial.
Publication|Articles|October 19, 2026
- October 2026
- Volume 92
- Issue 10
Peptide Compounding Is Evolving: What Pharmacists Need to Know Now
Author(s)Ned Milenkovich, PharmD, JD
Fact checked by: Yasmeen Qahwash
A summer PCAC vote pushes 6 peptide families toward the 503A bulks list—but the FDA's decision is still pending.
Advertisement
Advertisement
If you work anywhere near compounding, wellness, sports medicine, or longevity medicine, you have probably heard the names by now: BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon. Peptides have gone mainstream—or at least much closer to it.
Related to this article
Community pharmacies are access points, safe places, and sources of stability when everything else feels uncertain.
Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
Isatuximab on-body injector enables quick, hyaluronidase-free subcutaneous dosing, reducing reactions and easing multiple myeloma clinic workflows.
Pharmacy teams can prevent early discontinuation by setting clear expectations for when—and how—a medication's benefit will become apparent.
Pharmacists make a difference in patients’ lives through MTM services.
Phase 2 DeLLphi-309 data show comparable activity in previously treated SCLC with less frequent dosing.
The most enduring resources a preceptor can give students are the confidence and tools to ask deeper questions.
Advertisement
Advertisement